Jax DiEugenio

FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

May 28th 2025

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

May 28th 2025

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Awareness Efforts Aim to Improve Early Recognition and Multidisciplinary Care for Brain Tumors

May 28th 2025

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.

Bispecific Antibodies Gain Ground in Frontline Follicular Lymphoma Management

May 27th 2025

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

Dr Randall on Consensus Developed at The Annual Birmingham Orthopedic Oncology Meeting

May 27th 2025

R. Lor Randall, MD, FASCO, discusses key areas of consensus discussed at the Annual Birmingham Orthopedic Oncology Meeting.

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

May 27th 2025

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

CHMP Recommends EU Approval of Frontline Tislelizumab/Chemo for Metastatic Nasopharyngeal Carcinoma

May 27th 2025

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma

May 27th 2025

Eftilagimod alfa plus radiotherapy and pembrolizumab improved tumor hyalinization/fibrosis rates vs radiotherapy alone in resectable soft tissue sarcoma.

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

May 27th 2025

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

Full FDA Approval Underscores the Role of Larotrectinib in NTRK Fusion+ Solid Tumors

May 27th 2025

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

Treatment Gaps Persist in Advanced Melanoma as Trials Explore Options Beyond Standard Checkpoint and BRAF/MEK Inhibitors

May 27th 2025

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

Social Media Expands Access to Practical Public Health Education: With Chandler Park, MD; and Paul Hanona, MD

May 26th 2025

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

Dr Kahl on Persisting Unmet Needs in the Treatment of Mantle Cell Lymphoma

May 26th 2025

Brad Kahl, MD, discusses the ongoing unmet needs in the treatment of mantle cell lymphoma.

Dr McCann on the Biologic Heterogeneity Within HER2+ Breast Cancer

May 26th 2025

Kelly E. McCann, MD, PhD, discusses the biologic heterogeneity within HER2-positive breast cancer and highlights the clinical implications of HR status in this disease subset.

Statin Use Is Not Associated With Improved Outcomes in Early HER2+ Breast Cancer

May 22nd 2025

A post hoc analysis from the APHINITY trial showed statin use did not improve survival in early-stage HER2-positive breast cancer.

Dr Jain on Current Challenges in Defining Venetoclax Failure in CLL

May 21st 2025

How Unexpected Opportunities Shaped an Oncology Career Beyond the Clinic: With D. Ross Camidge, MD, PhD; and Lauren Meehan Machos, MPH

May 21st 2025

Camidge and Machos discussed Machos' early career transition from pre-med to sales, to her role in building strategic partnerships with key opinion leaders in oncology.

Dr Zonder on the Importance of Personalized Medicine in Multiple Myeloma

May 21st 2025

Jeffrey Zonder, MD, discusses the importance of personalized medicine in the treatment of multiple myeloma.

Pola-R-CHP Is Associated With Improved 2-Year PFS Rates in Older Untreated DLBCL Population

May 21st 2025

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

Dr Fakih on the FDA Approval of Retifanlimab for Advanced Anal Cancer

May 20th 2025

Marwan Fakih, MD, discusses the clinical relevance of the FDA’s approval of retifanlimab for patients with squamous cell carcinoma of the anal canal.